Compare HURC & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURC | SPRO |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 156.3M |
| IPO Year | 1995 | 2017 |
| Metric | HURC | SPRO |
|---|---|---|
| Price | $22.60 | $2.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.6K | ★ 1.6M |
| Earning Date | 06-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.59 | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,554,000.00 | $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $14.50 | $1.80 |
| 52 Week High | $23.75 | $3.08 |
| Indicator | HURC | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 71.11 | 40.10 |
| Support Level | $16.51 | $2.12 |
| Resistance Level | $23.75 | $2.50 |
| Average True Range (ATR) | 0.80 | 0.22 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 57.63 | 20.00 |
Hurco Companies Inc is an international industrial technology company that designs, manufactures, and sells computerized (CNC) machine tools for the metal cutting industry through a international sales and distribution network. Its proprietary control systems and software are sold as integral components of its machine tools. The Company also provides machine tool components, automation solutions, software options, upgrades, accessories, replacement parts, and related support services. It operates in the Americas, Europe, and Asia Pacific, with the Americas contributing the majority of revenue. Its core products include vertical and horizontal machining centers (mills), turning centers (lathes), and toolroom machines.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.